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INTRODUCTION
Heterozygous familial hypercholesterolemia (HeFH) affects about one in 200 to 250 persons or
over 30 million people worldwide, of whom about 20–25% are children and adolescents (1, 2).
In those with HeFH, the level of serum low-density lipoprotein cholesterol (LDL-C) is elevated
about two-fold from birth (3). If left untreated, the severe hypercholesterolemia causes pre-mature
atherosclerosis. The standard treatment in HeFH children is statin therapy, which should start
when the child is between 8 and 12 years of age (4). Homozygous familial hypercholesterolemia
(HoFH) is the severe form of familial hypercholesterolemia (FH) affecting approximately 1 in
300,000 persons worldwide and causing four- to five-fold elevated levels of serum LDL-C (5).
Despite the availability of multiple lipid-lowering therapies most HoFH patients do not achieve
sufficiently low LDL-C levels, and accordingly are at high risk of symptomatic atherosclerotic
cardiovascular disease already in childhood (6). In fact, there have been several case reports of
sudden cardiac death due to fatal myocardial infarction in children with HoFH before the age of
10 years (7). Of note, the majority of the clinical studies performed on FH patients have included
only the much more common form of FH, i.e., HeFH. Accordingly, when we refer to mere “FH,”
we refer to studies with HeFH patients, unless specified otherwise.
ENDOTHELIAL DYSFUNCTION IN FAMILIAL
HYPERCHOLESTEROLEMIA
The significantly elevated serum LDL-C causes endothelial dysfunction already in young children
with FH (8, 9). Additionally, many FH patients have raised serum levels of lipoprotein(a)
[Lp(a)] (10). Thus, endothelial function in FH children can be severely compromised when
both LDL-C and Lp(a) levels are increased (8). Moreover, compared with unaffected controls,
FH children display a proinflammatory and prothrombotic phenotype which is associated with
vascular dysfunction (11). Because Lp(a) is circulating in the blood, both proinflammatory
and antifibrinolytic (i.e., prothrombotic) effects may extend from the macrovascular to the
microvascular level, so affecting the entire circulatory system. Furthermore, because Lp(a) inhibits
fibrinolysis, the risk of forming non-occluding or occluding thrombi is increased in FH children,
in contrast to non-FH children with a primarily healthy endothelium (12).
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COVID-19–AN ENDOTHELIAL DISEASE
COVID-19 is considered to be an endothelial disease (13).
Thus, the effect of this disease on vessel wall endothelial
linings should particularly affect FH patients with COVID-
19, in whom the already dysfunctional endothelium is
acutely exposed to additional damaging insults caused by
the excessive immunoinflammatory response of the host
(i.e., the cytokine storm) and because the coronavirus can
damage the endothelial cells also directly thereby leading to
“endotheliitis” (13, 14). When exposed to inflammatory and
infectious signals, the normally anticoagulant, antithrombotic,
and profibrinolytic endothelial cells become activated and
locally promote the activation of the coagulation cascade and
thrombus formation. The pro-coagulant/pro-aggregatory,
pro-inflammatory, vasoconstrictor, pro-oxidant, and barrier
function-impairing properties of such damaged endothelium
then critically contribute to the multiorgan failure characteristic
of advanced stages of COVID-19.
COVID-19 IS A PROTHROMBOTIC STATE
A recent autopsy study revealed that adult COVID-19 patients
frequently have fibrin microthrombi in the heart without acute
ischemic injury (15). The risk of developing such non-occluding
or even occluding cardiac microthrombi is likely to be higher
in children with FH. According to the results of a recent meta-
analysis, among hospitalized adult patients with COVID-19, the
prevalence of acute myocardial infarction was 3.3% (95% CI
0.3–8.5) (16). Therefore, the possibility that children with FH,
particularly those with HoFH and COVID-19, are at increased
risk of coronary thrombus formation and, despite their young
age, may be at risk for an ischemic cardiac event (6).
Current data have demonstrated a COVID-19-induced
prothrombotic state in children, as reflected by elevated D-dimer
levels (17). This prothrombotic state can be further followed
in the clinical setting by using a diagnostic disseminated
intravascular coagulation (DIC) score, which has been
established by The International Society on Thrombosis
and Haemostasis (ISTH) (18, 19). The ISTH DIC score is taking
into account several mechanisms related to the DIC syndrome
which is characterized by widespread intravascular activation
of coagulation. The pathophysiological mechanisms include,
among others, cytokine-initiated inflammatory activation
of coagulation and insufficient control of anticoagulant
pathways, which together lead to endothelial dysfunction and
microvascular thrombosis (19). The usefulness of the ISTH DIC
score was shown in a retrospective large cohort study of 1,127
adult COVID-19 patients in Spain (20). In this study, the initial
ISTH DIC score was significantly higher among the ultimately
non-surviving patients.
Al-Ghafry et al. (21) recently published a case series of
eight hospitalized COVID-19 pediatric patients, in which the
coagulation profiles were determined. Six children had elevated
D-dimer levels and required oxygen supplementation, and
five children also required intensive care unit treatment. The
authors carried out rotational thromboelastometry and found
an increased blood clot firmness with a contribution from
fibrinogen. Based on these laboratory findings, the children of
whom the youngest were 8 years old received anticoagulation
according to institutional adult anticoagulation guidelines, and
no thromboembolic complications were observed in the treated
children. Based on the above findings there is a potential need to
expand and study the indication for prophylactic anticoagulation
in hospitalized children with COVID-19 (22) to children with
FH, provided there are no contraindications to anticoagulant
therapy. Furthermore, in FH children, it is essential to continue
effective statin therapy because statins not only improve
endothelial function but also decrease serum D-dimer levels by
about 15%, thus providing additional mild anticoagulation (23,
24). Moreover, because proprotein convertase subtilisin/kexin
type 9 (PCSK9) inhibitors effectively lower serum LDL-C
concentration, reduce the Lp(a) level by about 30%, and may
also enhance the antiviral action of interferon in patients
with hypercholesterolemia, the use of these inhibitors could be
considered in hospitalized pediatric FH patients with COVID-19,
particularly those with HoFH, if not already in use (25–27).
DISCUSSION
Results from controlled studies investigating the clinical effects
of anticoagulation in hospitalized children with COVID-19
are lacking. Meanwhile, Loi et al. (22) have recommended
that children with COVID-19 are eligible for anticoagulation.
Based on the considerations presented here and on a recent
expert consensus-based pediatric opinion (28), anticoagulant
prophylaxis in children should be carried out (in the absence of
any contraindications) by using low-dose low-molecular-weight
heparin. Loi et al. also recommend that, in hospitalized children
with COVID-19, it is important to trend the disseminated
intravascular coagulation score with attention to the D-dimer
level. Additionally, a pediatric risk assessment and consideration
of prophylactic anticoagulation to prevent thrombosis should be
performed at baseline and daily thereafter. When considering
that FH is a prothrombotic condition by itself, the above
recommendations would particularly apply to hospitalized FH
children with COVID-19 (10, 29). This idea is supported
by the above consensus-based clinical recommendation for
anticoagulation in children hospitalized for COVID-19-related
illnesses (28).
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